SOURCE: Geneart AG

July 12, 2007 01:00 ET

GENEART Acquires Gene Synthesis Patent

REGENSBURG, GERMANY--(Marketwire - July 12, 2007) -


- GENEART acquires the US Patent 6472184 "Method for Producing
Nucleic Acid Polymers".
- This acquisition provides GENEART with yet another proprietary
method to synthesize complex gene sequences.

Regensburg, July 12, 2007. Today, GENEART AG announces the acquisition of US patent 6472184 "Method for Producing Nucleic Acid Polymers". The patent-protected technology is used for the synthesis of complex gene sequences. The rights to this patent are a suitable fit to complement the GENEART patent portfolio. The seamless coverage of the production process is an important competitive advantage for GENEART in the collaboration with large customers in the pharmaceutical and chemical industry as well as in the biotechnology field.

Legal Information

This document may contain estimates, prognoses and opinions about company plans and objectives, products or services, future results, opinions about these results or opinions leading up to these results. All these projections into the future are subject to risk, uncertainty and unforeseeable change outside the control of the GENEART Group. Many factors may lead to actual results, which considerably deviate from the given projections for these results.

For further inquiries, please contact:

Bernd Merkl                    Frank Ostermair
GENEART AG                     Haubrok Investor Relations GmbH
Josef-Engert-Str. 11           Maximilianstr. 45
D-93053 Regensburg             80538 Munich
Tel.: +49-(0)941-942 76 - 38   Tel: +49-(0)89-461347-10
Fax: +49-(0)941-942 76 - 75    Fax: +49-(0)89-461347-29
ir@geneart.com                 f.ostermair@haubrok.de
www.geneart.com

Background Information

About GENEART AG

In 2000, GENEART entered the gene synthesis market and has since become the global market leader. Today, the company is one of the leading specialists in the synthetic biology field. Experts at GENEART provide key technologies for the development and production of new therapeutics and vaccines. Customers also take advantage of GENEART services to customize enzyme attributes, such as the attributes of enzymes used as detergent additives, and to construct bacteria, which produce complex biopolymers or break down polymers, such as synthetics, petroleum components, etc. Our production and service spectrum spans a wide range, from the production of synthetic genes according to DIN EN ISO 9001-2000, to the creation of gene libraries in the combinatorial biology, to the development and production of DNA-based biologically active substances. The GENEART AG in Regensburg (Germany) and the subsidiary GENEART Inc. in Toronto (Canada) employ more than 120 people. Since May 2006, GENEART is listed on the German Stock Exchange.





Copyright © Hugin ASA 2007. All rights reserved.

Contact Information